Shares of Cytokinetics are down 7% afterhours at $35.50 after resumption of trading. Shares had been halted since this morning pending the outcome of FDA AdCom vote on Omecamtiv Mecarbil, and the committee voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics (NASDAQ:CYTK) Stock Falls; Investors Disheartened by Heart Drug Problems
- Cytokinetics to resume trading at 18:15ET
- Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
- Cytokinetics: FDA panel says benefits of omecamtiv mecarbil do not outweigh risk
- FDA AdCom votes 8-3 against Cytokinetics drug, Bloomberg reports
